REG - OptiBiotix Health - Placing and Issue of Warrants

OptiBiotix HealthAnnouncement

23/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250523:nRSW8779Ja&default-theme=true

RNS Number : 8779J  OptiBiotix Health PLC  23 May 2025

 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Placing and Issue of Warrants

New Subsidiary

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business products which
reduce hunger and food cravings, enhance the gut microbiome, and sweet fibres
as healthy sugar substitutes, announces that it has raised £750,000 through
the issue of 5,357,143  new ordinary shares of 2 pence each ("Ordinary
Shares") in the Company ("Placing Shares") at a price of 14 pence per share
("Issue Price") ("Placing").

 

As part of the Placing, the Company has issued one warrant for every two new
Ordinary Shares subscribed for, exercisable at a price of 21 pence per share
for a period of 3 years from the date of Admission (as defined further below).

 

A new USA institutional investor subscribed for approximately £500,000 of new
Ordinary Shares as part of the Placing, with previous experience of investing
in companies with weight management products who became aware of OptiBiotix's
recent launches of SlimBiome products in the USA.

 

The net proceeds of the Placing will be utilised to include the following:-

 

·    Leasing a US warehousing and logistics facility, manufacturing and
warehousing 5-10 metric tonnes of SlimBiome in the USA to support partner
forecasts and the lead times (2-3 weeks) required by the growing number of
ecommerce and retail partners.  Current lead times are 12-16 weeks and
increasingly impacted by shipping companies taking longer to fill cargoes and
customs delays at USA ports.

·    Investing in growing sales with existing and new partners in the
USA.  The Company is seeing increased interest from established brands both
globally, and particularly in the USA, who are currently providing traditional
weight management products looking for science based ingredients with health
claims to bring functionality to existing well known, but declining product
ranges.

·    Increasing the number of new partners in Asia, India, Europe, and the
USA to reduce dependency on a limited range of partners in each territory

·    Investing in social media advertising to increase awareness of
OptiBiotix's own label products on Ecommerce platforms in India, including
Amazon, Flipkart, and HealthKart

 

New Subsidiary

The Company is pleased to announce that as part of its strategy of growing its
presence in the USA it has established a 100% owned subsidiary, OptiBiotix
Health USA.  This will help mitigate risks of tariffs and establish a
physical presence in a large and important market.

 

Admission

Application will be made to the London Stock Exchange to admit the Placing
Shares to trading on AIM ("Admission"). Admission of the new Ordinary Shares
is expected to occur on or around 30 May 2025. The new Ordinary Shares will
rank pari passu with the existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure and Transparency Rules, following Admission
the enlarged issued share capital of the Company will comprise 103,300,304
Ordinary Shares of 2p each. The above figure may be used by shareholders as
the denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
Company, under the Disclosure and Transparency Rules.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased that recent
product launches in the USA has attracted a new US institutional investor.
This investor has seen returns from previous investments in weight management
products and recognised the growth potential of our products.  The Company is
determined to ensure that funds raised are used to accelerate sales growth and
take the Company to profitability."

 

This announcement contains information which, prior to its disclosure, was
considered inside information for the purposes of the UK Market Abuse
Regulation and the Directors of the Company are responsible for the release of
this announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                             www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD)              Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Peterhouse Capital Limited (Broker)               Tel: 020 7220 9797
 Duncan Vasey/ Lucy Williams

 Walbrook PR Ltd                                   Mob: 07876 741 001
 Anna Dunphy

 

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions.  These forward looking statements are
not based on historical facts but rather on the Directors' current
expectations and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures (including the
amount, nature and sources of funding thereof), competitive advantages,
business prospects and opportunities. Such forward looking statements reflect
the Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEBIGDULDDDGUD